Advances in Therapy for Psoriasis: An Overview of Infliximab, Etanercept, Efalizumab, Alefacept, Adalimumab, Tazarotene, and Pimecrolimus

Title: Advances in Therapy for Psoriasis: An Overview of Infliximab, Etanercept, Efalizumab, Alefacept, Adalimumab, Tazarotene, and Pimecrolimus

Volume: 11 Issue: 2

Author(s): Ritu Saini, William D. Tutrone and Jeffrey M. Weinberg

Affiliation:

Keywords: psoriasis, biologic therapy, t cell, cytokine, infliximab, etanercept, efalizumab, alefacept, adalimumab, tazarotene

Abstract: Psoriasis is a chronic skin disorder that affects approximately 2% of the US and European population. Over the last several years, one of the major focuses in psoriasis research has been the development of biologic therapies for this disease. The aim of these therapies is to provide selective, immunologically directed intervention with fewer side effects than traditional therapies. The goal of this article is to review the progress of the biologic agents which are available, or under investigation for clinical use: infliximab, etanercept, efalizumab, alefacept, and adalimumab. In addition, two other investigational therapies, oral tazarotene and oral pimecrolimus will be discussed. Clinical data for these agents, including the most recent phase II and / or III study results, will be discussed, as well as the most recent safety data

Cite this article as:

Saini Ritu, Tutrone D. William and Weinberg M. Jeffrey, Advances in Therapy for Psoriasis: An Overview of Infliximab, Etanercept, Efalizumab, Alefacept, Adalimumab, Tazarotene, and Pimecrolimus, Current Pharmaceutical Design 2005; 11 (2) . https://dx.doi.org/10.2174/1381612053382232